Evidence map›Paper›PMID 24588402›Full record

ArticleJournal of neurochemistry2014

Alterations in STriatal-Enriched protein tyrosine Phosphatase expression, activation, and downstream signaling in early and late stages of the YAC128 Huntington's disease mouse model.

Clare M Gladding, Jing Fan, Lily Y J Zhang, Liang Wang, Jian Xu, Edward H Y Li, Paul J Lombroso, Lynn A Raymond

Open access · greenAbstract read
In one paragraph

Article in Journal of neurochemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Review
  3. Synaptic Dysfunction in Huntington's Disease: Lessons from Genetic Animal Models.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2022
    Article
  4. Review
  5. Review
  6. Article
  7. Altered Regulation of Striatal NeuronalFrontiers in synaptic neuroscience · 2019
    Article
  8. Review
  9. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Clare M GladdingDepartment of Psychiatry, Division of Neuroscience, Brain Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.
Jing Fan
Lily Y J Zhang
Liang Wang
Jian Xu
Edward H Y Li
Paul J Lombroso
Lynn A Raymond
University of British Columbia · CAYale University · US

Funding

MOLECULAR AND CELLULAR ANALYSIS OF BRAIN ENRICHED PTPSR01MH052711 · NIMH · YALE UNIVERSITY · PI LOMBROSO, PAUL J · 1999 to 2014
$5.0M
The Role of STEP in SchizophreniaR01MH091037 · NIMH · YALE UNIVERSITY · PI LOMBROSO, PAUL J · 2011 to 2015
$1.8M
MOLECULAR AND CELLULAR ANALYSES OF BRAIN ENRICHED PTPSR29MH052711 · NIMH · YALE UNIVERSITY · PI LOMBROSO, PAUL J · 1994 to 1998
–
NIMH NIH HHS MH091037NIMH NIH HHS MH52711NIMH NIH HHS R01 MH052711NIMH NIH HHS R01 MH091037
6 · The paper itself

Abstract

Striatal neurodegeneration and synaptic dysfunction in Huntington's disease are mediated by the mutant huntingtin (mHtt) protein. MHtt disrupts calcium homeostasis and facilitates excitotoxicity, in part by altering NMDA receptor (NMDAR) trafficking and function. Pre-symptomatic (excitotoxin-sensitive) transgenic mice expressing full-length human mHtt with 128 polyglutamine repeats (YAC128 Huntington's disease mice) show increased calpain activity and extrasynaptic NMDAR (Ex-NMDAR) localization and signaling. Furthermore, Ex-NMDAR stimulation facilitates excitotoxicity in wild-type cortical neurons via calpain-mediated cleavage of STriatal-Enriched protein tyrosine Phosphatase 61 (STEP61). The cleavage product, STEP33, cannot dephosphorylate p38 mitogen-activated protein kinase (MAPK), thereby augmenting apoptotic signaling. Here, we show elevated extrasynaptic calpain-mediated cleavage of STEP61 and p38 phosphorylation, as well as STEP61 inactivation and reduced extracellular signal-regulated protein kinase 1/2 phosphorylation (ERK1/2) in the striatum of 6-week-old, excitotoxin-sensitive YAC128 mice. Calpain inhibition reduced basal and NMDA-induced STEP61 cleavage. However, basal p38 phosphorylation was normalized by a peptide disrupting NMDAR-post-synaptic density protein-95 (PSD-95) binding but not by calpain inhibition. In 1-year-old excitotoxin-resistant YAC128 mice, STEP33 levels were not elevated, but STEP61 inactivation and p38 and ERK 1/2 phosphorylation levels were increased. These results show that in YAC128 striatal tissue, enhanced NMDAR-PSD-95 interactions contributes to elevated p38 signaling in early, excitotoxin-sensitive stages, and suggest that STEP61 inactivation enhances MAPK signaling at late, excitotoxin-resistant stages. The YAC128 Huntington's disease mouse model shows early, enhanced susceptibility to NMDA receptor-mediated striatal apoptosis, progressing to late-stage excitotoxicity resistance. This study shows that elevated NMDA receptor-PSD-95 interactions as well as decreased extrasynaptic STriatal-Enriched protein tyrosine Phosphatase 61 (STEP61) activation may contribute to early enhanced apoptotic signaling. In late-stage YAC128 mice, reduced STEP61 levels and activity correlate with elevated MAPK signaling, consistent with excitotoxicity resistance. Solid and dotted arrows indicate conclusions drawn from the current study and other literature, respectively.

Indexed as

Gene Expression Regulation, EnzymologicAnimalsApoptosisChromosomes, Artificial, YeastCorpus StriatumDisease Models, AnimalEnzyme ActivationHumansHuntington DiseaseMaleMiceMice, TransgenicOrgan Culture TechniquesProtein Tyrosine Phosphatases, Non-ReceptorSignal TransductionProtein Tyrosine Phosphatases, Non-ReceptorPtpn5 protein, mousecalpainextrasynapticHuntington's diseaseNMDA receptorp38 mitogen-activated protein kinase signalingSTriatal-Enriched protein tyrosine Phosphatase

Identifiers

PMID24588402
PMCPMC4065618
OpenAlexW2080316203

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.